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Abstract
Purpose The goal of sentinel lymph node biopsy is to establish the presence or absence of cancer cells in regional axillary 
nodes. The number of sentinel nodes harvested from each patient varies. The aim of this study was to determine what factors 
influence the number of sentinel nodes excised at sentinel node biopsy.
Methods Data from 426 patients with breast cancer who underwent sentinel lymph node biopsy at the Edinburgh Breast 
Unit by 10 different experienced breast surgeons were included in this analysis. Univariate and multivariable statistical 
analysis was performed.
Results In the multivariate analysis the number of sentinel nodes biopsied varied significantly between operating surgeon 
(p < 0.0001) and was also statistically associated with the use of neoadjuvant chemotherapy (p < 0.0001) and with the number 
of involved lymph nodes (p < 0.0001). More nodes were removed in patients who received neoadjuvant chemotherapy and 
had metastases in sentinel lymph nodes.
Conclusions This study shows that the surgeon plays a pivotal and significant role in determining the numbers of sentinel 
nodes removed by sentinel lymph node biopsy. Surgeons should monitor their own data on the average numbers of sentinel 
nodes they remove. Some surgeons may not be removing sufficient numbers of sentinel nodes to maintain a low false nega-
tive rate for this procedure.
Keywords Sentinel lymph node biopsy · Breast cancer · Treatment · Staging · Axilla
Introduction
The lymphatic system was discovered in 1653 by Bartholin. 
Virchow in the nineteenth century believed that lymph nodes 
filtered lymph [1]. The spread of cancer cells through the 
lymphatic system by a defined route stemmed from these 
observations and resulted in the technique of sentinel lymph 
node biopsy (SLNB). A sentinel node is named after the first 
guard who stands watch. Lymph flow from the tumour site 
passes through the first nodes draining the breast known as 
sentinel nodes [1]. A negative sentinel node biopsy assumes 
no metastasis to any axillary nodes. Metastatic breast can-
cer is present when cancer cells involve the sentinel node 
or nodes [2]. SLNB provides prognostic information and 
guides adjuvant treatment.
SLNB utilises intra-operative mapping of breast lym-
phatic drainage usually with a blue dye and isotope [1]. A 
sentinel lymph node in breast cancer surgery is defined as 
a blue node or a “hot” radioactive node and includes nodes 
other than the hottest node providing that it contains at least 
10% of the radioactivity of the hottest node [3]. The false 
negative rate of SLNB in breast cancer surgery falls with an 
increase in sentinel nodes removed [4]. In the NSABP B-32 
trial [5] one node gave a false negative rate of 17.7% whereas 
three or more nodes had a false negative rate of 4.8%. There 
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remains much variation between how many nodes surgeons 
remove and what comprises an adequate SLNB.
The primary aim of this study was to identify what fac-
tors influence the number of lymph nodes removed by sen-
tinel lymph node biopsy. This was assessed in the context 
of patients undergoing surgical treatment and sentinel node 
biopsy for breast cancer at the Edinburgh Breast Unit.
Methods
Database and study population
Data were collected retrospectively from the Edinburgh 
Breast Unit at the Western General Hospital, Edinburgh with 
the aim of acquiring 50 patients for each of the 10 experi-
enced breast surgeons. Patients with core biopsy diagnosed 
invasive or in situ breast cancer who underwent SLNB as 
part of breast conserving surgery or mastectomy were eli-
gible for inclusion in this study. Surgery dates ranged from 
March 2016 to September 2017. The hospital record sys-
tem, pathology reports and operating theatre diaries were 
used to identify patients. Sentinel node were identified using 
25 MBq of Technetium injected by the surgeon immediately 
after the induction of anaesthesia either under the nipple or 
intradermally over the cancer combined with 2 ml of Patent 
blue V injected in the sub and periareolar regions [6]. The 
breast was then massaged. No scintiscans were performed. 
The technique was standardised and all surgeons were 
trained in the technique by JMD as part of his requirements 
as a radioisotope license holder [6]. The surgeons included 
in this study were consultants, associate specialists or staff 
grade pure breast surgeons who had been performing sen-
tinel node biopsy for at least 5 years. Only axillary sentinel 
nodes were sampled. The standard definition of sentinel 
nodes was used in this study, that is nodes that were blue or 
had isotope counts of at least 10% of the hottest node. The 
number of sentinel nodes removed and used for analysis was 
the number found and reported by the pathologist. Surgeons 
also removed other axillary nodes if they were palpable or 
felt abnormal and these were recorded as sampled nodes.
Population characteristics
Four hundred and forty‐three patients had a histologically 
confirmed diagnosis of invasive or in situ breast cancer and 
had SLNB performed in the Edinburgh Breast Unit by one 
of ten surgeons. Seventeen patients were excluded because 
there was incomplete data on sentinel node numbers or 
SLNB was not performed. In patients who had a complete 
pathological response to neoadjuvant therapy, tumour size 
was not included in the analysis. An oestrogen receptor 
(ER) positive cancer was defined as a cancer with > 1% cells 
staining positively for ER by immunohistochemistry. ER lev-
els were classified on the Allred scale ranging from 0 to 8.
Statistical analysis
Distribution of data was determined to be non-normal using 
the Kolmogorov–Smirnov test and testing for equivalent 
mean and variance. Univariate analysis was performed 
using appropriate statistical tests as outlined in the results 
section. Multivariable analysis was carried out using IBM 
SPSS software to build a Poisson log linear main effects 
generalised linear model analysis based on the Wald Chi-
square statistic. Data collected included patient age, tumour 
size, tumour grade, type of surgery and surgeon, neoadjuvant 
chemotherapy (NAC), lympho-vascular invasion, number 
of confirmed positive sentinel lymph nodes and hormone 
and HER2 receptor status. Separate subset analyses were 
performed including and omitting patients who either (i) 
received neoadjuvant chemotherapy or (ii) had an involved 
node or nodes at diagnosis and received neoadjuvant chemo-
therapy, all of whom had one involved node clipped at diag-
nosis. p values ≤ 0.05 were considered to be of significance.
Results
Patient characteristics
Table 1 displays patient cohort data for a cohort of 426 
patients who met the inclusion criteria in relation to each 
variable for which data were collected. Average patient 
age was 61 years. The mean tumour size of this cohort was 
22.7 mm and the most commonly confirmed grade was grade 
2 disease.
Sentinel nodes were identified in 96.1% of patients in 
the cohort. In 17 patients, (3.9% of the cohort,) no senti-
nel nodes were identified. These patients had an axillary 
node sampling procedure and had an average of 4.5 axillary 
lymph nodes removed. This procedure has been validated in 
Edinburgh by a series of randomised trials. Only two of the 
patients (11.7%) having axillary sampling had histologically 
confirmed involved axillary lymph nodes.
The number of nodes removed per SLNB procedure 
across all patients (n = 426) is detailed in Fig. 1. The mean 
number of nodes removed was 2.35. As shown in Fig. 1, the 
data is non-normally distributed.
Univariate analysis
Univariate analysis revealed statistically significant associa-
tions between the number of sentinel lymph nodes sampled 
and surgeon (p < 0.0001), age of the patient (p < 0.0001), 
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Table 1  Baseline characteristics 
of patient cohort displayed in 
relation to each variable
SLNB sentinel lymph node biopsy, WLE wide local excision, MX mastectomy, RE-EX re-excision, DCIS/
LCIS ductal/lobular carcinoma in situ, ER oestrogen receptor, HER2 human epidermal growth factor recep-
tor 2
Variable Number % of cohort 
(N = 426)
Number of sentinel nodes biopsied
 0 17 4.0
 1–2 251 58.9
  ≥ 3 158 37.1
Total number of nodes removed including 426 sentinel nodes
 0 0 0
 1–2 287 53.4
  ≥ 3 250 46.6
Histologically confirmed node status
 Node negative 362 85.0
 Node positive 64 15
Histologically confirmed positive nodes by number of sentinel nodes biopsied
 Node positive with 1–2 sentinel nodes biopsied 27/251 (10.7%) 6.3
 Node positive with ≥ 3 sentinel nodes biopsied 33/158 (20.8%) 7.7
Patient age (years) at surgery
 30–40 14 3.3
 41–50 58 13.6
 51–60 119 27.9
 61–70 148 34.7
 71–80 64 15.0
 81–90 16 3.8
 91–100 3 0.7
 Missing data 4 0.9
Neoadjuvant chemotherapy
 Yes 40 9.4
 No 386 90.6
Lymphatic/vascular invasion
 Yes 61 14.3
 No 364 85.4
 Indeterminate 1 0.2
Primary type of surgery
 WLE SLNB 365 85.7
 MX SLNB 36 8.5
 Re-ex SLNB 10 2.3
 SLNB alone 15 3.5
Grade
 1 104 24.4
 2 233 54.7
 3 71 16.7
 Unknown 18 4.2
Tumour size (mm)
  < 10 61 14.3
 10–20 190 44.6
  > 20 157 36.8
 Unknown 18 4.2
Tumour hormone status
 ER + HER2 + 16 3.8
 ER + HER− 321 75.4
 ER−HER2 + 24 5.6
 ER−HER2− 54 12.7
 Unknown 11 2.6
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the use of neoadjuvant chemotherapy (p < 0.0001), num-
ber of confirmed histologically proven involved (positive) 
sentinel lymph nodes (p < 0.0001), tumour size (p < 0.001), 
tumour grade (p > 0.003) and ER status (p < 0.008). Greater 
numbers of sentinel lymph nodes were removed in women 
who were younger, received neoadjuvant chemotherapy, had 
larger tumours, had more involved axillary nodes, had higher 
grade cancers and had low ER levels (Allred scores < 5) or 
were ER negative.
Surgeon
Ten surgeons performed SNB with number of procedures 
per consultant ranging from 21 to 78 with a mean of 45.7 
(Fig. 2).
Univariate analysis using the Kruskal–Wallis test with 
Dunn’s multiple comparisons test showed a significant 
association between surgeon and number of sentinel lymph 
nodes biopsied (p < 0.0001) (Fig. 2). In particular, surgeon 
1 took a statistically significantly higher number of sentinel 
lymph nodes than surgeons 1, 3, 4, 5, 8 and 9. Nine of the 
ten surgeons took an average of less than three nodes per 
procedure.
Number of confirmed positive sentinel lymph nodes
Univariate analysis performed using the Mann–Whitney 
test revealed that significantly (p = 0.0028) greater num-
bers of sentinel lymph nodes were taken from patients who 
were subsequently confirmed to be node positive compared 
to the numbers of sentinel node samples from patients with 
node negative disease (Fig. 3).
Fig. 1  Histogram of number of sentinel nodes removed per SLNB 
procedure (frequency). Total number procedures, n = 444. See Online 
Appendix for raw data
Fig. 2  Boxplot graph showing the mean, upper and lower quartiles 
and 95% confidence intervals for number of SLNs biopsies for each 
surgeon (1–10). Stars represent statistical significance: * < 0.05, 
** < 0.01, *** < 0.001, **** < 0.0001). Pie charts under the graph 
illustrated the proportion of patients for each surgeon where no 
(blue), 1–2 (orange) or > 3 (grey) sentinel nodes were biopsied
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Neoadjuvant chemotherapy (NAC)
The average number of sentinel nodes excised in relation 
to whether patients had NAC is displayed in Fig. 4. Data 
regarding NAC were available for 426 patients, of whom 
40 (9.38%) received NAC. Those who received NAC in 
this study had a mean of 3.5 nodes sentinel lymph nodes 
removed, whereas those without NAC had a mean of 2.2 
nodes, statistically significant using the Mann–Whitney 
test (3.5 ± 2.2 vs 2.2 ± 1.4, p < 0.0001). Of the cohort who 
received NAC (N = 40), 62.5% had 3 or more sentinel lymph 
nodes removed compared to 37% of the cohort who did not 
receive NAC. When sampled nodes are included, the mean 
number of nodes removed increased to 4.6 and 83.3% of 
patients after NAC had 3 or more nodes sent to pathology.
Twenty-eight of the 40 patients (70%) who received NAC 
were node negative at diagnosis, the mean number of senti-
nel nodes removed in this group was 3.32 and 18 of these 28 
patients (64.2%) had 3 or more sentinel nodes removed. In 
the 10 patients who had less than 3 sentinel nodes removed 5 
(50%) had other nodes sampled increasing the mean number 
of nodes removed in these 10 patients from 1.5 to 2.8.
Twelve women who received NAC were node positive at 
diagnosis and the mean number of sentinel nodes removed in 
these patients was 3.75. Seven of these 12 patients (58.3%) 
had 3 or more sentinel nodes removed but when sampled 
nodes were included, 10/12 (83.3%) had 3 or more nodes 
sent to pathology.
Fig. 3  Boxplot graph showing the mean (2.23 for node negative and 
3.03 for node positive), upper and lower quartiles and 95% confidence 
intervals comparing sentinel nodes sampled between patients who 
were histologically determined to be node negative and those who 
were node positive. Blue: node negative, orange: node positive. Stars 
represent statistical significance: *** < 0.001)
Fig. 4  a Comparison of mean with 95% confidence intervals of 
number of SLN’s removed at biopsy in patients who did and did not 
receive NAC. Stars denote p-value < 0.0001 using Mann–Whitney 
statistics. b Pie charts of percentages of patients who had no, 1–3 or 
4  + sentinel node biopsies split by those who did (lower) and did not 
(upper) receive NAC
 Breast Cancer Research and Treatment
1 3
Generalised linear modelling for multivariable 
analysis
Multivariable analysis in the whole series showed a sig-
nificant association between the number of nodes removed 
at sentinel node biopsy and surgeon (p < 0.0001), the use 
of neoadjuvant chemotherapy (p < 0.0001) and number of 
involved sentinel lymph nodes (p < 0.0001) (Table 2).
Separate multivariable analyses were performed in 
the subsets of patients who did and did not receive NAC 
(n = 40 and n = 386 respectively). In both subsets the 
most statistically significant explanatory variables were 
surgeon, number of confirmed positive lymph nodes, and 
patient age, with higher numbers of sampled sentinel 
lymph nodes in younger patients who were subsequently 
found to have more extensive node positive disease. In the 
subset who received NAC, tumour grade was also found to 
be significant (Table 2).
Within the subset who received NAC (n = 40), sepa-
rate multivariable analyses were performed for both the 
30% of these patients who were lymph node positive at 
diagnosis and the 70% who were not. Only the number of 
confirmed positive sentinel lymph nodes correlated sig-
nificantly with the number of SLNs biopsied in patients 
who were lymph node negative at diagnosis, with higher 
numbers of sentinel nodes removed in patients with node 
positive disease. The number of patients who were lymph 
node positive at diagnosis and received NAC was small 
(12 patients) but in this group, the surgeon was the only 
statistically significant explanatory variable correlating to 
the number of SLNs biopsied. Table 2 shows the results 
of the multivariate analysis for the subset patient cohorts. 
There was no significant association between the number 
of nodes removed and any subsequent axillary treatment.
Discussion
This study has shown that a variety of factors have an 
impact on the number of sentinel nodes identified using 
isotope and blue dye that were removed during sentinel 
node biopsy. Some factors are easy to explain. Almost 
Table 2  Significant explanatory variables from the multivariable generalised liner model analysis for the full cohort (blue) and subset patient 
cohorts (yellow & green)
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10% of patients in this series had NAC. Significantly more 
SLN’s were removed in the group after NAC compared to 
patients who did not receive NAC. Almost two thirds of 
NAC patients had at least 3 sentinel nodes removed with 
an average of 3.5 nodes removed per patient. Recent guid-
ance [7, 8] advocates that in patients who have proven 
lymph node metastases at diagnosis that revert to normal 
clinically post NAC then at least three nodes should be 
removed. In this study 83.3% of women in this group had 
three or more nodes removed, up to 40% of patients with 
involved nodes in the axilla can be converted to node nega-
tive by NAC [8]. Current optimal management includes 
marking at least one involved node at diagnosis and post 
NAC ensuring that the marked node together with two or 
more sentinel nodes are removed, a procedure known as 
targeted axillary dissection [4, 8, 9]. Our results are from 
a time when practice was evolving but our practice is con-
sistent with guidelines and all patients in this series with 
involved nodes had a clip placed in one involved node and 
removal of the clipped node was achieved in all patients 
in this series.
Cancers that, develop in younger women are more likely 
to have a biologically aggressive phenotype [10] and are 
more likely to be triple negative or HER2 positive and be 
node positive. In this series younger women had signifi-
cantly more sentinel nodes removed than older women. 
The same findings were seen with tumour size and tumour 
grade. Younger women, because they have larger tumours 
and higher grade tumours are more likely to be node posi-
tive. Surgeons know the patients age, tumour size and 
grade prior to surgery. Whether they consciously or uncon-
sciously remove more nodes in such patients is not clear 
but that could explain why older patients in this series had 
less sentinel nodes removed. Alternatively, transmission 
of isotope and blue dye through lymphatics might reduce 
with age. Another explanation for these observations is 
that these factors are surrogates for node status explaining 
why these factors dropped out of significance in the multi-
variable analysis. Involved axillary nodes are palpable and 
thus are easier to identify and this is likely to explain why 
surgeons remove more sentinel nodes in patients whose 
nodes are involved.
Regardless of any influence of patient age or tumour 
biology, this study showed the most significant factor 
explaining the variation in the number of SLN’s removed 
was the surgeon. This demonstrates a potential weakness 
in the SLNB procedure because it is not completely stand-
ardised. Surgeon 2 removed an average of 3.3 nodes com-
pared to surgeon 9 who took a mean of 1.8 (p < 0.0001) 
and surgeon 5 took a mean 1.9 (p < 0.001). Part of the 
variation can be explained by differences in the patients 
operated on by different surgeons. Some surgeons in 
this study had a higher percentage of patients who had 
sentinel node biopsies after NAC. For instance, Surgeon 
10 operated on more patients who had NAC (28.6% of the 
operations they performed) and the mean size of tumours 
they operated on was 32.47 mm, compared to surgeon 4 
who operated on the smallest proportions of patients who 
received NAC (4.3%) and the average size of tumours for 
this surgeon was 20.04 mm (Supplementary Fig. 3). Thus, 
some of the variation in the numbers of sentinel nodes 
removed between surgeons can be explained by other fac-
tors. Despite this, the multivariable model retained sur-
geon as a major factor. Whatever the explanation, there 
are significant differences between surgeons, and one must 
conclude that either some surgeons are taking too many 
nodes or others are taking too few.
Studies such as NSABP B-32 [5] showed that although 
there was a significant false negative rate with lower num-
bers of nodes removed, there was no obvious impact on the 
numbers of axillary recurrences. There is therefore no great 
concern that surgeons removing fewer axillary nodes will 
have a higher axillary recurrence rate. There is however evi-
dence that because removing less nodes increases the false 
negative rate [4, 5]. Thus between 10 and 15% of patients 
having only one or two nodes have a false negative sentinel 
node and so may not receive appropriate systemic therapy 
given that axillary lymph node status plays an important role 
in adjuvant therapy decisions. Thus, removing less nodes 
results not only in qualitative information being lost (node 
positive or node negative), but also quantitative information 
on the numbers of nodes involved if less nodes are removed. 
Patients who have one out of one node involved may receive 
a different systemic treatment to a patient with two out of 
two or three out of three nodes involved so one can see how 
increasing the numbers of nodes retrieved at sentinel node 
biopsy might impact on adjuvant treatment decisions. We 
found no variation in axillary treatment related to the num-
ber of nodes removed.
In a large report based on SEER data [11], there was a 
significantly better survival for patients who had 3 nodes 
removed compared to patients with 1 or 2 involved nodes: 
Hazard Ratio of 0.73 CI 95% [0.60–0.88], p < 0.001. This 
improvement in survival was largely driven by the poorer 
outlook in the group who had only one SLN removed. The 
implications of this study are that the optimal number of sen-
tinel lymph nodes that should be removed is three. The cur-
rent study shows some surgeons consistently remove three 
or more nodes and others do not. This questions whether sur-
geons whose average lymph node retrieval rate is less than 
two are removing all the sentinel nodes and that this poten-
tially under-stages some patients with subsequent impli-
cations for their systemic therapy and long-term outlook. 
What must also be considered is whether some surgeons are 
removing too many sentinel node. In Edinburgh, we have 
conducted a series of studies looking at the morbidity of 
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both sentinel node biopsy as part of the UK ALMANAC 
study and axillary node sampling as part of a series of stud-
ies performed in Edinburgh [12–14]. Maxillary sampling 
involves removing four nodes from the lower maxilla by 
palpation and study of removing four nodes had minimal 
long-term arm morbidity in very carefully designed prospec-
tive studies [15]. Concerns about removing too many nodes 
are real but providing the number is four or less then our 
long-term data shows morbidity is very small in removing 
this number of maxillary lymph nodes. The current study 
suggests that the number of sentinel nodes removed per sur-
geon perhaps should become a quality measure collected 
by each surgeon and audited and considered at their annual 
appraisal. Surgeons removing consistently too many or too 
few sentinel nodes need then to amend their practice. Since 
the presentation of this study to the surgeons in the unit, 
there has been a clear change and the variation is now much 
less than it was during this study.
This study is strengthened by the sample size of 426 pro-
cedures from the largest breast unit in the UK and provides 
a meaningful analysis of current breast cancer care. A single 
centre analysis is important in removing some of the vari-
ables such as technique and consistent pathology reporting. 
The exclusions from the study were small because the Edin-
burgh Breast Unit collects all pathology data and pathology 
reporting is consistent in all cases. The largest amount of 
missing data was on grade and that was missing in only 
3.99%. The study was largely successful at getting approxi-
mately 50 cases from each of the 10 surgeons. Most surgeons 
were consultants but also included were associate special-
ists and staff grade surgeons. All were experienced breast 
surgeons and no trainees were included in this study. Future 
analysis of this patient cohort to investigate the relation-
ship between the number of SLN’s biopsied and adjuvant 
treatment as well as mortality would determine whether the 
number of nodes removed is a significant factor in relation to 
prognosis, however this was beyond the scope of this study 
at present.
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